October 27, 2 2014 For Immediate Release For Immediate Release: MedTestt Announces Acquisition of Clinitox D Diagnostix (Canton, Michigan) MedTest M Holdings (“MedTest”), the pparent companny of MedTeest DX and P Pointe Scientific, has signed a definitive agreement to t acquire C Clinitox Diagnnostix locateed in Mississsauga, Ontario, Canada. MeedTest is an in-vitro diagnostics com mpany providding automatted, fast and costeffective blood and urine u testing solutions for diabetes, caardiovascular disease, urinne drugs of abuse screening and wellnesss testing. Clinitox Diagnostix D was founded in n 2010 by Ho oward Lee. C Clinitox Diaggnostix providdes drugs of abuse confirmattory testing capabilitiess via liquid d chromatoggraphy/mass spectrophottometry (LC C/MS) instrumen ntation and associated reeagents and consumable s as pre-pacckaged kits. Implemenntation consulting g provides thee customer with w on-site assistance in seetting up theirr LC/MS testiing and develloping the standaard operating procedures en nabling the laaboratory to innitiate testingg sooner and rreduce costlyy startup costs. Hanjoon Ryu, R CEO of MedTest, staated: “The ad ddition of Clinnitox Diagnosstix to our porrtfolio enablees us to becomee a highly diff fferentiated prrovider of exttensive solutioons in the druugs of abuse testing markett. Now we can c provide th he laboratory with confirm matory drugs oof abuse testinng capability in addition too the urine drug gs of abuse sccreening testin ng that can bee performed oon the Mindraay™ BS-200 and BS-480 Chemistry y Analyzers. Our clinical expertise e in th he drugs of abbuse testing m market meets both individuual laboratory y testing need ds as well as th he needs of th he growing huub-and-spokee regional toxxicology networks.” In additio on to manufaccturing and diistribution off reagents, callibrators and quality contrrol products ffor the general ch hemistry and d drugs of ab buse testing markets, m MeddTest is the eexclusive US S distributor oof the Mindray™ ™ floor modeel BS-480 Cheemistry Analy yzer and the bbench-top BS S-200 Chemisstry Analyzerr. The acquisition of Clinitox x enables MedTest to provide a morre integrated service offerring of innovvative instrumen nts with pro oven quality reagents, superior s custtomer suppoort and recoognized econnomic advantagees. For additiional information, please contact: c W MT T(ASCP)SC Debbie Whitehair, Vice President, Marketting 1603 484-748-1 [email protected] om www.med dtest.com PR-M3111-0 01 10/14